Total contracts reached 44 between January and May, 4.4 times the previous year's annual figure
Germany formally introduced AI reimbursement for lung cancer screening in April; Coreline Europe (CLE) reported 477% first-quarter revenue growth
Early adoption by Charité and other leading academic hospitals is creating a pathway for broader deployment across regional and private healthcare networks
The launch of Germany's national lung cancer screening program is beginning to reshape the competitive landscape of medical artificial intelligence. As screening moves from pilot initiatives to nationwide implementation, the market's focus is shifting away from standalone algorithm performance and toward platforms capable of supporting the entire screening workflow.
Against this backdrop, Coreline Soft has emerged as one of the early beneficiaries of the transition, rapidly expanding its presence in Germany's lung cancer screening market and strengthening its position ahead of wider adoption.
The company signed 10 new hospital contracts in Germany throughout 2025. In the first quarter of 2026 alone, however, it secured 11 new agreements, surpassing its previous annual total within a single quarter.
The pace accelerated further in the following months. Coreline Soft signed 12 additional contracts in April and another 21 in May, bringing the total number of new German contracts between January and May to 44. That figure represents a 4.4-fold increase compared with the company's full-year performance in 2025. The 21 contracts signed in May alone exceeded the previous year's annual total by more than two times.
Germany’s National Screening Program Is Redefining AI Competition
Industry observers view the growth as more than a sales achievement. Rather, it is increasingly being interpreted as an early indicator of structural demand created by Germany's national lung cancer screening framework.
On April 1, 2026, Germany officially incorporated low-dose CT (LDCT)-based lung cancer screening into its statutory health insurance (GKV) system. The policy allows high-risk smokers to receive screening under public insurance coverage, prompting hospitals across the country to accelerate preparations for large-scale screening programs and AI deployment.
What makes the German market particularly significant is that lung cancer screening extends far beyond image acquisition and nodule detection.
In practice, screening programs require a complex operational infrastructure that includes double reading by radiologists, quality assurance (QA), longitudinal patient management, GDPR-compliant data pseudonymization, and multi-center reading workflows. As a result, hospitals and national screening systems increasingly require more than a diagnostic algorithm. They need a platform capable of supporting the entire screening process in a reliable and scalable manner.
Recent academic research suggests that this shift is not unique to Germany but reflects a broader transformation across the European screening landscape.
A study published in the journal European Radiology compared 16 CE-certified AI products designed for lung cancer screening and found that competitive differentiation is increasingly determined not by detection accuracy alone but by how comprehensively a solution supports the full screening workflow. Researchers highlighted functions such as growth-rate assessment, malignancy prediction, structured reporting, and longitudinal follow-up management as becoming increasingly important within national screening programs.
The study emphasized that lung cancer screening is not a one-time diagnostic event. It requires continuous comparison with prior CT scans, assessment of disease progression, scheduling of follow-up examinations, and standardized reporting over extended periods. In this context, platform capabilities are becoming as important as detection performance.
Among the products evaluated, AVIEW LCS was identified as one of the solutions providing the broadest coverage of lung cancer screening tasks among the 16 CE-certified systems reviewed.
The findings help explain why hospitals participating in Germany's national screening rollout appear increasingly focused on platform-based solutions that can be integrated into operational workflows rather than relying solely on stand-alone AI detection tools.
Against this backdrop, Coreline Soft's combination of AVIEW LCS Plus and AVIEW HUB is increasingly viewed as well aligned with the needs of the German market.
AVIEW LCS Plus analyzes not only pulmonary nodules but also a range of clinically relevant findings from a single chest CT scan, including chronic obstructive pulmonary disease (COPD) and coronary artery calcification (CAC). AVIEW HUB complements these capabilities by supporting multi-center reading, double reading workflows, data integration, quality management, and privacy-compliant workflow operations.
Industry analysts note that Coreline Soft's differentiation lies in its ability to provide both AI-powered clinical analysis and the operational infrastructure required for a national screening program.
How Early Market Entry Is Creating a Durable Advantage
The quality of the company's clinical references further strengthens its position.
Coreline Soft is collaborating with several of Germany's leading medical institutions, including Charité University Hospital, Heidelberg University Hospital, and Hannover Medical School (MHH). These organizations operate under some of Europe's most demanding standards for clinical workflow management, data standardization, and quality control.
Successful deployment in such environments is widely regarded as a strong validation of both technological reliability and real-world applicability.
Charité offers a particularly notable example. Industry sources indicate that most appointments for this year's lung cancer screening program were booked early, reflecting rapidly growing demand among eligible participants. Observers see this as evidence that Germany's national screening initiative is moving beyond its initial rollout phase and entering a period of sustained operational expansion.
Participation in the workflow of one of Europe's most prestigious hospitals may also generate a powerful reference effect as adoption spreads across Germany's regional and private healthcare networks, as well as neighboring European markets.
Beyond market share gains, the development is notable for what it may mean for future revenue quality.
Initial software deployments and installation contracts often serve as leading indicators for usage-based revenue streams. As screening volumes increase within Germany's public insurance framework, recurring revenues tied to AI utilization are expected to accumulate over time.
Such a model offers a transition away from one-time software sales toward a recurring revenue structure linked directly to national screening activity, improving revenue visibility and long-term predictability.
Early market leadership may also create meaningful barriers to entry.
National screening programs involve complex requirements related to data integration, regulatory compliance, quality assurance, and coordination among healthcare providers. Companies that establish operational references and workflow integration early in the market cycle often enjoy advantages that competitors may find difficult to replicate.
In this sense, operational integration can become a durable economic moat that extends beyond pure technological performance.
The scalability of the platform presents another strategic advantage.
The chest CT workflow established for lung cancer screening can potentially be expanded to additional disease areas, including COPD, cardiovascular disease, and interstitial lung disease. Because AVIEW LCS Plus is designed to extract and structure multiple clinical insights from a single CT scan, healthcare providers can obtain broader diagnostic information without requiring additional imaging procedures.
This approach may improve both cost efficiency for healthcare systems and convenience for patients.
Beyond Germany, Coreline Soft continues to expand its footprint across Europe through participation in major screening initiatives, including Italy's RISP project, France's IMPULSION program, the United Kingdom's NHS EDIN project, and the TIDL project led by Norway's Akershus University Hospital (AHUS).
Ultimately, the developments unfolding in Germany suggest that medical AI is entering a new phase of adoption. The industry is moving beyond the stage of proving algorithmic performance and toward integration within national healthcare infrastructure.
As this transition accelerates, competitive advantage is likely to be defined less by accuracy alone and more by the ability to support clinical workflows, regulatory requirements, quality assurance processes, and long-term patient management. Viewed through that lens, Coreline Soft's recent contract growth may represent more than company-specific momentum; it may offer an early glimpse into how Europe's emerging national screening market is beginning to take shape.
